News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
257,256 Results
Type
Article (13763)
Company Profile (264)
Press Release (243229)
Section
Business (79246)
Career Advice (147)
Deals (13176)
Drug Delivery (29)
Drug Development (50212)
Employer Resources (31)
FDA (5649)
Job Trends (5105)
News (143789)
Policy (10016)
Tag
Academia (902)
Africa (145)
Allergies (30)
Alliances (21422)
Alzheimer's disease (693)
Antibody-drug conjugate (ADC) (33)
Approvals (5619)
Arizona (39)
Artificial intelligence (40)
Asia (16682)
Australia (2796)
Bankruptcy (96)
Best Places to Work (4385)
Biotechnology (221)
Breast cancer (36)
C2C Services and Suppliers (10644)
California (1380)
Canada (539)
Cancer (382)
Career advice (128)
CAR-T (36)
Cell therapy (111)
China (102)
Clinical research (39232)
Collaboration (118)
Colorado (47)
Compensation (57)
Connecticut (48)
COVID-19 (988)
Cystic fibrosis (61)
Data (335)
Diabetes (46)
Diagnostics (1168)
Earnings (28377)
Europe (35827)
Events (45992)
Executive appointments (115)
FDA (5810)
Florida (144)
Funding (124)
Gene editing (32)
Gene therapy (91)
GLP-1 (267)
Government (1058)
Healthcare (6512)
Hotbed/Location (184215)
Illinois (87)
Indiana (45)
Infectious disease (1003)
Inflammatory bowel disease (80)
IPO (7147)
Job creations (857)
Job search strategy (124)
Kansas (52)
Layoffs (178)
Legal (1372)
Lung cancer (78)
Manufacturing (44)
Maryland (216)
Massachusetts (1131)
Medical device (2525)
Medtech (2526)
Mergers & acquisitions (6061)
Metabolic disorders (156)
Michigan (39)
Minnesota (71)
Neuroscience (829)
New Jersey (368)
New York (440)
NextGen Class of 2024 (1983)
Non-profit (838)
North Carolina (347)
Northern California (600)
Obesity (89)
Ohio (66)
Opinion (87)
Parkinson's disease (45)
Patents (37)
Pennsylvania (306)
People (24780)
Pharmaceutical (42)
Phase I (13763)
Phase II (18237)
Phase III (11609)
Pipeline (95)
Postmarket research (845)
Preclinical (5788)
Radiopharmaceuticals (199)
Rare diseases (116)
Real estate (1408)
Regulatory (8071)
Research institute (929)
South America (207)
Southern California (572)
Startups (1965)
Texas (130)
United States (5233)
Vaccines (142)
Washington State (164)
Weight loss (62)
Date
Today (49)
Last 7 days (387)
Last 30 days (1603)
Last 365 days (21177)
2024 (15859)
2023 (22414)
2022 (26825)
2021 (27809)
2020 (23363)
2019 (16231)
2018 (11741)
2017 (13750)
2016 (11846)
2015 (14360)
2014 (10415)
2013 (7498)
2012 (7538)
2011 (7622)
2010 (7431)
257,256 Results for "heron therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2024 and highlighted recent corporate updates.
May 7, 2024
·
15 min read
Policy
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle (“VAN”)
Heron Therapeutics, Inc., a commercial-stage biotechnology company, announced the Prior Approval Supplement submission to the U.S. Food and Drug Administration for ZYNRELEF® extended-release solution Vial Access Needle.
May 29, 2024
·
7 min read
Business
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
September 3, 2024
·
3 min read
Biotech Bay
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference.
March 28, 2024
·
1 min read
Biotech Beach
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
Heron Therapeutics, Inc., a commercial-stage biotechnology company, announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET.
April 11, 2024
·
2 min read
Business
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Heron Therapeutics, Inc. today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m. ET to report first quarter 2024 financial results and discuss recent business highlights.
April 24, 2024
·
2 min read
Business
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2023 and highlighted recent corporate updates.
March 12, 2024
·
16 min read
Business
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
August 6, 2024
·
15 min read
Business
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
July 30, 2024
·
2 min read
CrossLink Life Sciences and Heron Therapeutics Partner to Boost ZYNRELEF® Promotion for Post-Operative Pain
Life Sciences, a leading medical device distributor and sales organization, is proud to announce a groundbreaking five-year partnership with Heron Therapeutics, Inc
January 11, 2024
·
1 min read
1 of 25,726
Next
